0001193125-12-205299.txt : 20120626 0001193125-12-205299.hdr.sgml : 20120626 20120502182412 ACCESSION NUMBER: 0001193125-12-205299 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALLERGAN INC CENTRAL INDEX KEY: 0000850693 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 951622442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2525 DUPONT DRIVE CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 7142464500 MAIL ADDRESS: STREET 1: P.O. BOX 19534 CITY: IRVINE STATE: CA ZIP: 92713-9534 CORRESP 1 filename1.htm Correspondence

[ALLERGAN LETTERHEAD]

May 2, 2012

VIA EDGAR CORRESPONDENCE

Jim B. Rosenberg

Senior Assistant Chief Accountant

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re: Allergan, Inc.

Form 10-K for the Fiscal Year Ended December 31, 2011

Filed February 28, 2012

File No. 001-10269

Dear Mr. Rosenberg:

We are responding to your letter dated May 1, 2012, regarding the review of the above-referenced filing. Pursuant to our discussion today with Tabatha Akins, Staff Accountant, we hereby confirm that Allergan, Inc. (the “Company”) intends to provide the Staff of the Division of Corporate Finance with the Company’s response to the Staff’s comments on or before May 30, 2012.

If you have any questions or comments with regard to this response or other matters, please call me at (714) 246-4815.

 

Very truly yours,

/s/ James F. Barlow

James F. Barlow

Senior Vice President, Corporate Controller

(Principal Accounting Officer)

 

cc: Jeffrey L. Edwards

Arnold A. Pinkston

Matthew J. Maletta

Tabatha Akins